'Antibodies 1998, molecular, cellular & clinical aspects', held in New York on 22 to 24 April 1998, was the fifth meeting in the series of international symposia organised by the Cancer Research Institute (CRI). The CRI was founded in 1953 with the objective of elucidating the role of immunity in cancer and applying this information to cancer treatment and prevention. From the beginning, the CRI recognised that advances in cancer immunology depended on advances in fundamental immunology and, for this reason, the Institute commits a major proportion of its resources to the support of basic immunological research. To carry out its mission, CRI has created a broad array of funding activities, including a Fellowship Program, an Investigator Program for immunologists initiating their independent academic careers, a clinical trials program of phase l-ll studies of cancer immunotherapy, and an Award Program to celebrate important achievements in the fields of immunology and cancer immunology. Six years ago, CRI inaugurated an international symposium series to provide a forum in which to focus on the two major objectives of cancer immunology -the development of antibody-based therapies and the development of vaccine-based therapies for cancer, and each year the focus alternates between these two approaches to cancer immunotherapy.
The purpose of this most recent meeting, organised by Drs. L. J. Old, of the Ludwig Institute for Cancer Research, J. V. Ravetch, of Rockefeller University, New York, and E. Pure, of the Wistar Institute, Philadelphia, was to perform a survey of the many advances recently made in comprehending the molecular and cellular biology of the humoral immune response, and to review the current state of monoclonal antibodybased therapies, with an emphasis on the potential which antibodies by themselves, acting via their biological effector functions, may have as cancer therapeutics as well as in diseases other than cancer.
From the discovery of MoAbs to the current clinical trials
The discovery of monoclonal antibodies (MoAbs) in 1975 was followed by a decade of exaggerated and unsophisticated expectation about their use as a powerful anticancer tool. The discouraging results of the earlier clinical trials then produced a prolonged period of deep demise and disappointment that seems now to be ending.
Indeed, the general failure of initial attempts to use MoAbs in cancer therapy was mainly due to two major problems. The immunogenicity of murine MoAbs in humans (antibodies generated in mice for eventual therapeutic use in humans showed limited effectiveness because the human immune system reacts against them as foreign) and the fact that murine antibodies generate only a weak recruitment of the effector functions (e.g., antibody-dependent cytotoxicity) that are needed for the antibody biological activity. Dr. L. G. Presta (Genetech Inc. San Francisco, CA) discussed the problems posed by designing molecules capable of overcoming the above-cited limitations of murine MoAbs and described recent advances in the production of engineered MoAbs which nowadays allows the replacement of murine MoAbs with 'chimeric' antibodies (produced by substitution of an entire intact variable domain of a human antibody with one from a non-human antibody) or with 'humanised' antibodies (in which only the six antigen-binding loops or complementarity-determining regions of the human antibody are substituted). Therefore, the immunogenicity of mouse antibodies in humans that generally precluded retreatment is no longer an insurmountable obstacle to assessing the therapeutic potential of MoAbs. Antibody chimerization and humanisation have gone a long way toward solving this problem. However, the design of humanised antibodies is not always straightforward and each antibody may present specific challenges. For instance, an anti-human protein C antibody that was recently humanised for its potential utility in controlling tumour vascularisation had a much greater dependence on calcium for binding to protein C zymogen than did the parent murine antibody.
Another humanised MoAb with important therapeutic potential was developed at the Genetech Inc., Herceptin a MoAb directed against the HER2 growth factor receptor which in 25% to 30% of patients with breast cancer is overexpressed on the tumour cells' surface where it plays an important role in the tumour progression by signalling the cells to reproduce. Recent clinical trials showed that Herceptin alone produced an overall response rate of 16% in metastatic breast cancer. Moreover, its addition to chemotherapy -either paclitaxel or doxorubicin plus cyclophosphamide -also increased by 50% or more both the response rate and the response duration over those of the same chemotherapy regimens given alone.
Other novel ways to construct human antibodies have been presented that may constitute powerful approaches by which to create reagents that can be administered repeatedly over a long period of time, characteristics that are essential for a cancer therapeutic.
New technological developments
Dr. A. Jakobovits's group, of Abgenix, Inc., Fremont, CA, is developing a new technology for the production of human monoclonal antibodies. By introducing megabase-sized fragments of the human heavy and kappa light chain loci into the germline of mice deficient in murine antibody production they generated three strains of mice that produce human immunoglobulins. Notably, the humoral response in these mice closely resembles in all respects that seen in humans, including gene rearrangement, assembly and repertoire. The so-called XenoMouse® can generate high-affinity fully human antibodies to multiple antigens, including human antigens such as interleukin-8 and tumournecrosis factor-alpha.
A different approach was followed by the group of Dr. Z. Eshhar of the Weizmann Institute of Science, Rehovot, Israel. Moving from the observation that tumour-specific cytotoxic T lymphocytes are very active but their usage for adoptive immunotherapy is strongly limited by their rarity, Dr. Eshhar has developed a method by which to customise and expand the spectrum of recognition of cytotoxic T cells. By endowing theT cell with a chimeric receptor gene consisting of antibody variable regions combined with the antibody's cell activating domain, he can direct theT cell to recognise a predefined target. Using three different chimera designs, Dr. Eshhar has demonstrated in preclinical models that these T-bodies' can recognise antigen, trigger T-cell activation, and target and kill cancerous cells. However, the feasibility and efficacy of this T-body approach in immunotherapy of cancer in humans has still to be established.
Dr. Pfreundschuh, at the Universitatskliniken der Saarlanes, Homburg, Germany, has developed bispecific monoclonal antibodies (BiMAbs) that recruit effector cells of the immune system to specific tumour sites. In particular, he has generated antibodies that bind to the CD30 antigen on the neoplastic cells of Hodgkin's disease on one end and to either T cells
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antigens (CD3 and CD28) or NK cells antigens (CD16) on the other. Both in vitro and clinical studies have demonstrated the promise of this approach. Specific combinations of these BiMAbs elicited apoptosis (programmed cell death) and necrosis of Hodgkin's tumour cells, as well as complete remissions of Hodgkin's-derived tumours in SCID mice. Furthermore, in phase l-ll clinical trials, about one-third of patients with Hodgkin's disease refractory to chemotherapy or radiotherapy achieved responses to BiMAb treatment, including regression of bulky mediastinal and retroperitoneal disease. The availability of recombinant humanised BiMAbs targeted to several types of human tumours may in the near future enlarge the therapeutic potential for this novel and interesting approach.
And at last some clinical data
Other presentations focused on the results of clinical trials. Dr. A. J. Grillo-Lopez, IDEC Pharmaceuticals Corporation, San Diego, reviewed the current clinical experience with Rituxan (Rituximab, IDEC-C2-B8), the first monoclonal antibody to receive FDA approval for the treatment of cancer and the first single agent to obtain FDA approval specifically for the treatment of lymphoma. Rituximab binds to the CD20 antigen. This antigen is found on over 90% of B-cell lymphomas and plays a role in cell cycle initiation and differentiation. Clinical trials demonstrate that patients with low-grade or follicular non-Hodgkin's lymphomas respond well, and with tolerable side effects, to Rituximab infusions. Dr. Grillo-Lopez described these studies in which an overall response rate of 50% was seen. Notably, the activity of this antibody is maintained in chemotherapy-resistant follicular lymphomas and in patients who relapsed after autologous transplantation. In vitro laboratory studies demonstrate that Rituximab works by altering complement-dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC). In addition, it induces the addition of phosphate groups to tyrosine residues, inhibits proliferation and induces apoptosis (programmed cell death) of lymphoma cells.
Dr. G. Riethmuller, University of Munich, Germany, discussed the reasons for the failure of the earlier MoAbs clinical trials with monoclonal antibodies that, according to the rules of classical drug development, included only patients with advanced cancers. In addition, a comparison between patients with solid tumours and patients with lymphoma or leukaemia in clinical trials who were treated with monoclonal antibodies found that objective remissions had occurred more frequently in the latter group. Together, these results have forced investigators to wonder whether patients with minimal residual disease might benefit from antibody treatment. In fact, Dr. Riethmuller has shown in a randomised trial of 190 patients with early colorectal cancer that those who were treated with the 17-1A antibody after complete surgical resection of A. J. Grillo-Lopez, MD their disease exhibited, after seven years of follow-up evaluation, a 32% increase in overall survival and a 23% decreased recurrence rate with significant reduction of distant metastases. Furthermore, randomised trials on over 3000 patients with colon cancer are underway to test in the adjuvant setting the combination of 5-fluorouracil plus the 17-1A antibody in comparison with the standard 5-fluorouracil regimens.
Dr. A. M. Scott, of the Ludwig Institute for Cancer Research, Melbourne, Australia, is developing chimeric and humanised antibodies that target specific tumours. Recombinant MoAbs directed against glycolipid (such as the ganglioside GD3) and carbohydrate antigens expressed on neurodefrmal and epithelial tumours demonstrated the most potent cytotoxic activity. One of these antibodies, KM871, reacts with the GD3 glycolipid and is now being tested in clinical trials in patients with metastatic melanoma. The laboratory studies revealed that KM871 stimulates complementdependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) via its Fc receptor. Additionally, Dr. Scott is studying a second antibody directed against the carbohydrate antigen Le y , which is expressed on the majority of epithelial tumours such as breast, colon, ovary, and lung cancers. Called Hu3S193, this antibody stimulated CDC and ADCC. HuS193 is now entering clinical trials for cancers that arise from epithelial cells.
Considering together all of the data presented at the meeting, it appears that we are entering a time of cautious optimism with respect to the general inclusion of antibody-based approaches in the therapy of cancer and possibly of other non-neoplastic diseases (indeed, data were presented from early clinical trials showing activity of the anti-TNFa cA2 antibody in rheumatoid arthritis and Chron's disease). To optimise the clinical results, however, the appropriate choice of antigenic targets on cancer cells will remain a crucial issue.
The excitement that followed presentation at the 1998 ASCO meeting held in May in Los Angeles of the encouraging results of the above-cited human trials of Herceptin seems to confirm that the clinical use of monoclonal antibodies (MoAbs) for cancer therapy may finally have come of age.
Emanuele Zucca
Lyon Consensus Conference on high-dose therapy in diffuse large-cell lymphoma
The results of the 1993 consensus conference on highdose therapy with autologous stem cell transplantation have been regarded as highly authoritative and for several years they have served as reference. New data, particularly from large-scale and randomised studies have since appeared, and recommendations can now be made with greater certitude for each disease. The challenge of the organizers of this meeting (B. Coiffier, T. Philippe, J. Armitage, M. Siemann) was to reach a consensus on the indications and modalities of high-dose therapy and stem cell transplantation for diffuse large cell lymphoma.
The first difference noted by the participants between this meeting and the previous one was the venue: Lyon's new Palais des Congres is impressive for its architectural conception, location and facilities, and it was a pleasure to meet in such a place. In addition, the overall organization of the meeting was excellent.
The consensus meeting was planned in accord with the NIH guidelines which recommend choosing a very narrow topic (high-dose chemotherapy in diffuse large cell lymphoma) to scrutinize by a standardised procedure: the majority of the data under discussion were provided to the participants in advance as a supplement to Annals of Oncology (1998; 9 (Suppl 1)), together with the questions to be answered by the jury. The jury itself was composed of ten authorities in the field and chaired by M. Shipp. None of the jury members were personally involved with high-dose therapy and their judgements were thus unbiased.
The jury members was asked 57 questions, but the two principal ones were when to transplant, and how to transplant. Two entire days of presentations by wellprepared speakers were devoted to each of these two questions, providing a really comprehensive overview of the data which has accumulated over the past 20 years in this exciting field. While not very large, the audience was highly qualified, and this became apparent during the relevant discussions (which occasionally turned into heated debates). Nevertheless, both the presentation of the data and the discussions reflected the fact that in the lymphoma field the main problem remains a lack of solid data: only very few large randomised trials are available and of necessity the answers to many of the questions began with "I feel that... ".
The conclusion of the jury can be summarised as
